Eric S. Daar MD
Professor of Medicine, UCLA-David Geffen School of Medicine
Join to View Full Profile
21840 Normandie AveSte 700Torrance, CA 90502
Phone+1 310-222-5101
Fax+1 310-320-5463
Dr. Daar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Cedars-Sinai Medical CenterFellowship, Infectious Disease, 1988 - 1991- Cedars-Sinai Medical CenterResidency, Internal Medicine, 1985 - 1988
Georgetown University School of MedicineClass of 1985
Certifications & Licensure
CA State Medical License 1986 - 2027
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2003-2014
- Top Doctors:LA Area Castle Connolly, 2013
- Top Doctors:Southern California Castle Connolly, 2012
- Join now to see all
Clinical Trials
- The Biology of HIV Transmission Start of enrollment: 1999 Oct 01
- Outcomes of Anti-HIV Therapy During Early HIV Infection Start of enrollment: 1999 Oct 01
- Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination
- Join now to see all
Publications & Presentations
PubMed
- 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Abatacept.Nandita Nadig, Adarsh Bhimraj, Kelly Cawcutt, Kathleen Chiotos, Amy L Dzierba
Clinical Infectious Diseases. 2025-09-09 - Rapid Elimination of Culturable SARS-CoV-2 With Intramuscular or Intravenous Administration of Antiviral Monoclonal Antibody Therapy.Rinki Deo, Manish C Choudhary, Owen T Glover, Rachel Bender Ignacio, Julie Boucau
Open Forum Infectious Diseases. 2025-09-01 - 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Infliximab.Nandita Nadig, Adarsh Bhimraj, Kelly Cawcutt, Kathleen Chiotos, Amy L Dzierba
Clinical Infectious Diseases. 2025-08-20
Journal Articles
- Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men1Jill S Blumenthal, Eric S Daar, Centers for Disease Control and Prevention
- Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men1Jill S Blumenthal, Eric S Daar, Centers for Disease Control and Prevention
- Safety and Impact of Low-Dose Methotrexate on Endothelial Function and Inflammation in Individuals with Treated Human Immunodeficiency Virus: AIDS Clinical Trials Grou...Steven G Deeks, James H Stein, Carl Fichtenbaum, Judith S Currier, Priscilla Y Hsue, Eric S Daar, Ahmed Tawakol, Michael Lederman, Tanvir Bell, Diane Havlir, Clinical Infectious Diseases
- Join now to see all
Other
- Evaluation of the treatment-experienced patient with drug-resistant HIV infectionDaar ES, Lagnese M
http://www.uptodate.com/contents/evaluation-of-the-treatment-experienced-patient-with-drug-resistant
UpToDate, Wolters Kluwer Health - 2012-12-21 - Selection of antiretroviral therapy for the treatment-experienced patient with drug-resistant HIV infectionDaar ES, Lagnese M
http://www.uptodate.com/contents/selection-of-antiretroviral-therapy-for-the-treatment-experienced-p
UpToDate, Wolters Kluwer Health - 2013-01-24
Authored Content
- Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men1November 2018
Press Mentions
Risks of Removing Ovaries at Benign Hysterectomy May Outweigh the Benefits for Women at Low Risk for Ovarian CancerApril 17th, 2023- At IDWeek, New Insights into Long COVIDOctober 21st, 2022
- ACTIV-2d, a Global Phase 3 Trial of Novel Investigational COVID-19 Oral Antiviral Agent, LaunchesAugust 22nd, 2022
- Join now to see all
Grant Support
- An integrated intervention using a pill ingestible sensor system to trigger actions on multifaceted social and behavioral determinants of health among PLWHUNIVERSITY OF CALIFORNIA LOS ANGELES2023–2028
- Clinical Trial: A Phase IIIB, Randomized, Trial Of Open-Label Efavirenz Or AtazaNational Center For Research Resources2010
- Clinical Trial: A Phase III Comparative Study Of Three Non-Nucleoside Reverse TRNational Center For Research Resources2010
- California Neuroaids Tissue Network (CNTN)National Center For Research Resources2010
- A Longitudinal Study Of Cerebral And Neurocognitive FunctionNational Center For Research Resources2009–2010
- Long-Term Metabolic Assessments In Subjects Treated With Emtricitabine/TenofoNational Center For Research Resources2007–2010
- California Neuro AIDS Tissue NetworkNational Center For Research Resources2004–2010
- A Phase II/III Randomized, Double-Blind, Placebo-Controlled TriaNational Center For Research Resources2009
- Clinical Trial: A Phase II/III Randomized, Double-Blind, Placebo-Controlled TriaNational Center For Research Resources2008
- Acute HIV Infection And Early Disease Research Program (AIEDRP)National Center For Research Resources2005–2008
- California Neuro - AIDS Tissue NetworkNational Center For Research Resources2004–2008
- Pathogenesis Of Primary HIV InfectionNational Center For Research Resources1998–2008
- The Setpoint Study - A Randomized Study Of The Effect Of Immediate TreatmentNational Center For Research Resources2007
- A Phase III, Randomized, Open-Label, Comparison Of Lopinavir/Ritonavir PLUS ENational Center For Research Resources2005–2007
- Phase III, Randomized, Open-Label, Comparison Of LopinNational Center For Research Resources2004
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
